NDTV Profit on MSN
Lupin's Pune Facility Gets Four Observations After US FDA Inspection
The US FDA conducted a product-specific pre-approval inspection at the company’s Pune biotech facility from Sept. 8 to Sept.
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has signed an exclusive licensing agreement with South Korea’s Kwangdong Pharmaceutical Co., Ltd. for the rights to develop and commercialize OCU400, Ocugen’s ...
Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1 Filing based on four Phase 3 studies that met all primary and co-primary endpoints.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback